Your session is about to expire
← Back to Search
Alkylating agent
MM-398 + Cyclophosphamide for Solid Tumors
Phase 1
Waitlist Available
Research Sponsored by South Plains Oncology Consortium
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new cancer drug combo to see what the highest safe dose is.
Eligible Conditions
- Refractory or Recurrent Solid Tumors
- Rhabdomyosarcoma
- Osteosarcoma
- Neuroblastoma
- Bone Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: MM-398 + cyclophosphamideExperimental Treatment1 Intervention
MM-398+cyclophosphamide
Find a Location
Who is running the clinical trial?
South Plains Oncology ConsortiumLead Sponsor
6 Previous Clinical Trials
49 Total Patients Enrolled
Paul Harker-Murray, MDStudy ChairMidwest Children's Hospital
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have severe heart failure, irregular heartbeats or uncontrolled high blood pressure.Your disease has worsened after receiving prior treatment for advanced or spreading cancer.You have recently participated in another medical research study.You have significant digestive problems.
Research Study Groups:
This trial has the following groups:- Group 1: MM-398 + cyclophosphamide
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.